https://www.insideprecisionmedicine.com/topics/oncology/targeted-therapy-helps-high-risk-pediatric-hodgkins-lymphoma/
The targeted therapy brentuximab vedotin has significantly reduced relapse rates among children with high-risk Hodgkin's lymphoma.
Create an account
or login to join the discussion